A method comprising administering an agent, for example a PCSK9 inhibitor, to a patient who suffers from fatty liver disease or is at risk of fatty liver disease, thereby reducing the risk of fatty liver disease, severity of fatty liver disease, symptoms of such disease, or signs of such disease and a method comprising administering a PCSK9 inhibitor to a patient having symptoms of elevated liver enzymes to ameliorate said symptoms.
